Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 36

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Coffee Consumption and the Progression of NAFLD: A Systematic Review

Sewter, Rebecca, Heaney, Susan, Patterson, Amanda·2021·Nutrients
DOI 10.3390/nu13072381
Open this paper in CoChat — free account

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in developed countries. Coffee is one of the most consumed beverages in the world and has been shown to be beneficial in limiting progression in chronic liver disease in general. However, research surrounding the impact of coffee consumption on NAFLD progression is limited. This systematic review aimed to investigate the relationship between coffee consumption and the progression of liver disease, specifically for cases of NAFLD. MEDLINE, EMBASE, CINAHL, the Cochrane Library, and Scopus were searched for published studies that evaluated the effects of coffee consumption on the progression of NAFLD. The results are presented in a narrative synthesis with principal summary measures, including odds ratios, p-values, and differences in mean coffee intake in relation to severity of NAFLD. Five studies met the inclusion criteria and were included in this review. There was no trial evidence among NAFLD patients, rather all studies were of a cross-sectional design. Using the Academy of Nutrition and Dietetics Quality Criteria Checklist, four studies received a positive rating, with the remaining study receiving a neutral rating. Overall, four out of the five studies reported a statistically significant relationship between coffee consumption and the severity of fibrosis. Methods around capturing and defining coffee consumption were heterogeneous and therefore an effective dose could not be elucidated. Results suggest that higher coffee consumption is inversely associated with the severity of hepatic fibrosis in individuals with NAFLD. However, further research is required to elucidate the optimum quantity and form/preparation of coffee required to exert this hepatoprotective role.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu13072381

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 34

  1. Iser, 2013, Fatty liver disease—A practical guide for GPs, Aust. Fam. Physician, 42, 444
  2. Arrese, 2014, The prevalence of non-alcoholic fatty liver disease in the Americas, Ann. Hepatol., 13, 166, 10.1016/S1665-2681(19)30879-8 · DOI
  3. Mahady, 2018, Burden of non-alcoholic fatty liver disease in Australia, J. Gastroenterol. Hepatol., 33, 1, 10.1111/jgh.14270 · DOI
  4. Lucas, 2018, A systematic review of the present and future of non-alcoholic fatty liver disease, Clin. Exp. Hepatol., 4, 165, 10.5114/ceh.2018.78120 · DOI
  5. Kneeman, 2012, Secondary causes of non-alcoholic fatty liver disease, Ther. Adv. Gastroenterol., 5, 199, 10.1177/1756283X11430859 · DOI · Paper page
  6. Dyson, 2014, Non-alcoholic fatty liver disease: A practical approach to diagnosis and staging, Front. Gastroenterol., 5, 211, 10.1136/flgastro-2013-100403 · DOI · Paper page
  7. Whitsett, 2015, Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review, World J. Hepatol., 7, 2041, 10.4254/wjh.v7.i16.2041 · DOI
  8. Mehta, 2010, Review: Advances in the treatment of non-alcoholic fatty liver disease, Ther. Adv. Gastroenterol., 1, 101
  9. Sawangjit, R., Chongmelaxme, B., Phisalprapa, P., Saokaew, S., Thakkinstian, A., Kowdley, K., and Chaiyakunapruk, N. (2016). Comparative efficacy of interventions on non-alcoholic fatty liver disease (NAFLD). Medicine, 95. · DOI
  10. Golabi, 2016, Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review, World J. Gastroenterol., 22, 6318, 10.3748/wjg.v22.i27.6318 · DOI
  11. Valenzuela, 2015, Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease, Int. J. Mol. Sci., 16, 25168, 10.3390/ijms161025168 · DOI
  12. Chen, 2014, Coffee and non-alcoholic fatty liver disease: Brewing evidence for hepatoprotection?, J. Gastroenterol. Hepatol., 29, 435, 10.1111/jgh.12422 · DOI
  13. Morisco, 2014, Coffee and Liver Health, J. Clin. Gastroenterol., 48, S87, 10.1097/MCG.0000000000000240 · DOI
  14. Liu, F., Wang, X., Wu, G., Chen, L., Hu, P., Ren, H., and Hu, H. (2015). Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis. PLoS ONE, 10. · DOI
  15. Kennedy, 2016, Systematic review with meta-analysis: Coffee consumption and the risk of cirrhosis, Aliment. Pharmacol. Ther., 43, 562, 10.1111/apt.13523 · DOI
  16. Saab, 2014, Impact of coffee on liver diseases: A systematic review, Liver Int., 34, 495, 10.1111/liv.12304 · DOI
  17. Wijarnpreecha, 2017, Coffee consumption and risk of non-alcoholic fatty liver disease, Eur. J. Gastroenterol. Hepatol., 29, 8, 10.1097/MEG.0000000000000776 · DOI
  18. Catalano, 2010, Protective Role of Coffee in Non-alcoholic Fatty Liver Disease (NAFLD), Dig. Dis. Sci., 55, 3200, 10.1007/s10620-010-1143-3 · DOI
  19. Leoni, 2018, Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis, World J. Gastroenterol., 24, 3361, 10.3748/wjg.v24.i30.3361 · DOI
  20. Uribe, 2012, High coffee intake is associated with lower grade non-alcoholic fatty liver disease: The role of peripheral antioxidant activity, Ann. Hepatol., 11, 350, 10.1016/S1665-2681(19)30931-7 · DOI
  21. Zhou, 2019, Long-term coffee consumption, caffeine metabolism genetics, and risk of cardiovascular disease: A prospective analysis of up to 347,077 individuals and 8368 cases, Am. J. Clin. Nutr., 109, 509, 10.1093/ajcn/nqy297 · DOI
  22. Torres, 2013, Is It Time to Write a Prescription for Coffee? Coffee and Liver Disease, Gastroenterology, 144, 670, 10.1053/j.gastro.2013.02.015 · DOI
  23. Modi, 2009, Increased caffeine consumption is associated with reduced hepatic fibrosis, Hepatology, 51, 201, 10.1002/hep.23279 · DOI
  24. Shen, 2014, Association between caffeine consumption and non-alcoholic fatty liver disease: A systematic review and meta-analysis, Am. J. Gastroenterol., 109, 158
  25. Kennedy, O.J., Roderick, P., Buchanan, R., Fallowfield, J.A., Hayes, P.C., and Parkes, J. (2017). Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: A systematic review and dose–response meta-analysis. BMJ Open, 7. · DOI · Paper page
  26. Brandt, A., Nier, A., Jin, C.J., Baumann, A., Jung, F., Ribas, V., García-Ruiz, C., Fernández-Checa, J.C., and Bergheim, I. (2019). Consumption of decaffeinated coffee protects against the development of early non-alcoholic steatohepatitis: Role of intestinal barrier function. Redox Biol., 21. · DOI
  27. Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration, J. Clin. Epidemiol., 62, e1, 10.1016/j.jclinepi.2009.06.006 · DOI · Paper page
  28. (2020). Covidence Systematic Review Software, Veritas Health Innovation.
  29. Molloy, 2011, Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis, Hepatology, 55, 429, 10.1002/hep.24731 · DOI
  30. Bambha, 2014, Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis, Liver Int., 34, 1250, 10.1111/liv.12379 · DOI
  31. Anty, 2012, Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese european women with NAFLD undergoing bariatric surgery, J. Hepatol., 57, 1090, 10.1016/j.jhep.2012.07.014 · DOI
  32. Barros, 2016, Non-alcoholic steatohepatitis in morbid obese patients: Coffee consumption vs. disease severity, Ann. Hepatol., 15, 350, 10.5604/16652681.1198804 · DOI
  33. Salomone, 2014, Coffee consumption and non-alcoholic fatty liver onset: A prospective study in the general population, Transit. Res., 165, 428
  34. Chen, 2019, A systematic review and a dose-response meta-analysis of coffee dose and non-alcoholic fatty liver disease, Clin. Nutr., 38, 2552, 10.1016/j.clnu.2018.11.030 · DOI · Paper page

Cited by

Metadata

Authors
Sewter, R., Heaney, S., & Patterson, A.
Venue
Nutrients
Publisher
MDPI AG
Published
2021-07-12
Volume
13
Issue
7
Pages
2381
ISSN
2072-6643
DOI
10.3390/nu13072381
Cited by
36
References
2
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.